Last update 16 Apr 2026

Tetravalent influenza vaccine(MDCK Cells)( Chengdu Xinnuoming)

Overview

Basic Info

Drug Type
Prophylactic vaccine, Multivalent vaccine
Synonyms-
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
Infectious DiseasesRespiratory Diseases
Active Indication
Influenza, Human
Inactive Indication-
Originator Organization
Chengdu Olymvax Biopharmaceuticals, Inc.Chengdu Olymvax Biopharmaceuticals, Inc.Lanzhou Bailing Biotechnology Co., Ltd.Lanzhou Bailing Biotechnology Co., Ltd.Chengdu Xinnuoming Biotechnology Co., Ltd.
Active Organization
Chengdu Olymvax Biopharmaceuticals, Inc.Chengdu Olymvax Biopharmaceuticals, Inc.Shenzhen Kangtai Biological Products Co., Ltd.Shenzhen Kangtai Biological Products Co., Ltd.Lanzhou Bailing Biotechnology Co., Ltd.Lanzhou Bailing Biotechnology Co., Ltd.
Inactive Organization-
License Organization
Lanzhou Bailing Biotechnology Co., Ltd.Lanzhou Bailing Biotechnology Co., Ltd.Chengdu Xinnuoming Biotechnology Co., Ltd.
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with Tetravalent influenza vaccine(MDCK Cells)( Chengdu Xinnuoming)
CTR20254267
/ Active, not recruitingPhase 3
评价四价流感病毒裂解疫苗（MDCK细胞）在3岁及以上人群中接种的免疫原性和安全性的随机、盲法、阳性对照IIIa期临床试验
[Translation] A randomized, blinded, positive-controlled phase IIIa clinical trial evaluating the immunogenicity and safety of a quadrivalent influenza virus split vaccine (MDCK cell) in individuals aged 3 years and older.
CTR20250319
/ Active, not recruitingPhase 1
评价四价流感病毒裂解疫苗（MDCK细胞）在6月龄及以上人群中接种的安全性和初步免疫原性的随机、盲法、阳性对照Ⅰ期临床试验
[Translation] A randomized, blinded, positive-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of quadrivalent influenza virus split vaccine (MDCK cells) in people aged 6 months and above
CTR20261447
/ Not yet recruitingPhase 1
评价四价流感病毒裂解疫苗（MDCK细胞）在3周岁及以上人群中接种的安全性的随机、盲法、安慰剂对照Ⅰ期临床试验
[Translation] A randomized, blinded, placebo-controlled phase I clinical trial evaluating the safety of quadrivalent influenza virus split vaccine (MDCK cell) in individuals aged 3 years and older.
100 Clinical Results associated with Tetravalent influenza vaccine(MDCK Cells)( Chengdu Xinnuoming)
Login to view more data
100 Translational Medicine associated with Tetravalent influenza vaccine(MDCK Cells)( Chengdu Xinnuoming)
Login to view more data
100 Patents (Medical) associated with Tetravalent influenza vaccine(MDCK Cells)( Chengdu Xinnuoming)
Login to view more data
100 Deals associated with Tetravalent influenza vaccine(MDCK Cells)( Chengdu Xinnuoming)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 3
China
Chengdu Olymvax Biopharmaceuticals, Inc.Chengdu Olymvax Biopharmaceuticals, Inc.
30 Oct 2025
Influenza, HumanPhase 3
China
Lanzhou Bailing Biotechnology Co., Ltd.Lanzhou Bailing Biotechnology Co., Ltd.
30 Oct 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free